T cells and T cell tumors efficiently generate antigen-specific cytotoxic T cell immunity when modified with an NKT ligand by Chung, Yeonseok et al.
© 2012 Landes Bioscience.
Do not distribute.
T cells and T cell tumors efficiently generate
antigen-specific cytotoxic T cell immunity
when modified with an NKT ligand
Yeonseok Chung,
1,5 Young-Hee Lee,
1 Yongliang Zhang,
1 Natalia Martin-Orozco,
1 Tomohide Yamazaki,
1 Dapeng Zhou,
2
Chang-Yuil Kang,
4 Patrick Hwu,
2 Larry W. Kwak
3 and Chen Dong
1,*
1Department of Immunology; Center for Cancer Immunology Research; University of Texas MD Anderson Cancer Center; Houston, TX USA;
2Department of Melanoma Medical
Oncology; Center for Cancer Immunology Research; University of Texas MD Anderson Cancer Center; Houston, TX USA;
3Department of Lymphoma and Myeloma; Center for
Cancer Immunology Research; University of Texas MD Anderson Cancer Center; Houston, TX USA;
4College of Pharmacy; Seoul National University; Seoul, Republic of Korea;
5Institute of Molecular Medicine; University of Texas Medical School; Houston, TX USA
Keywords: cytotoxic T cell, iNKT cell, a-galactosylceramide, cellular vaccine, tumor immunity, CD1d
Various Invariant NKT (iNKT) cell ligands have been shown as potent adjuvants in boosting T cell reactivates to antigens
on professional APC. Non-professional APC, such as T cells, also co-expressing MHC class I and CD1d, have been
unattractive cell vaccine carriers due to their poor immunogenicity. Here, we report that T cells as well as T cell
lymphoma can efficiently generate antigen-specific cytotoxic T lymphocytes (CTL) responses in mice in vivo, when
formulated to present iNKT ligand a-galactosylceramide (aGC) on their surface CD1d. Vaccination with aGC-pulsed EG-7
T-cell lymphoma induced tumor-specific CTL response and suppressed the growth of EG-7 in a CD8 T cell-dependent
manner. Injection of aGC-loaded CD4 T cells in mice efficiently activated iNKT cells in vivo. While T cells loaded with a
class I-restricted peptide induced proliferation but not effector differentiation of antigen-specific CD8 T cells, injection of
T cells co-pulsed with aGC strongly induced IFNc and Granzyme B expression in T cells and complete lysis of target cells
in vivo. Presentation of aGC and peptide on the same cells was required for optimal CTL response and vaccinating T cells
appeared to directly stimulate both iNKT and cytotoxic CD8 T cells. Of note, the generation of this cytotoxic T cell
response was independent of IL-4, IFNc, IL-12, IL-21 and costimulation. Our data indicate that iNKT cell can license a
non-professional APC to directly trigger antigen-specific cytotoxic T cell responses, which provides an alternative cellular
vaccine strategy against tumors.
Introduction
CD1d-restricted invariant NKT cells (iNKT) recognize glycolipid
antigens presented on non-classical MHC class I-like molecule,
CD1d. Recent studies revealed a crucial role of iNKT cells in
the host defense against pathogens and tumors through direct
interaction with microbial antigens or indirect activation.
1
Moreover, iNKT cell acts as a bridge between innate and
acquired immune system by regulating T cell activation and
function. For instance, iNKT ligands have been shown with
strong potency in enhancing T cell responses to soluble protein
antigens or tumor antigens presented by professional antigen-
presenting cells (APC). Co-administration of a-galactosylceramide
(aGC) and protein antigens generates the antigen-specific CD4 T
and CD8 T cell immunity in vivo.
2,3 The generation of antigen-
specific adaptive immunity depends on the activation and
maturation of dendritic cells (DC) after aGC injection which
triggers IFNc and TNFa expression from iNKT cells.
2,4
Costimulation such as CD40 and CD80/CD86 is required for
the T cell immunity in this case.
4 Furthermore, injection of DC-
associated aGC induces the activation and expansion of iNKT
cells and NK cells in vivo in tumor patients.
5,6
Non-professional APC in immune system, such as T cells,
express both MHC class I and CD1d. The expression of MHC
class I on these cells may allow them to be protected from NK cell-
mediated cytotoxic attack through interaction with inhibitory
receptors.
7 The role of CD1d expression on peripheral T cells in
iNKTcellbiologyisnotyetclear, althoughitiswellestablishedthat
CD1d expression on thymic T cells is essential for positive selection
of iNKT cell.
8,9 DC has been shown to be the most efficient APC
for iNKT cell priming when aGC was injected as a soluble form,
while other types of cell expressing CDld suppress iNKT cell
activation in this condition.
10 In addition to DC, vaccination with
B cells copulsed with aGC and tumor-derived peptide generates an
efficient anti-tumor CD8 T cell response in several murine tumor
models.
11 Furthermore, our recent study showed that autologous B
lymphoma vaccine, manipulated to present aGC, can establish
memory anti-tumor T cell immunity.
12 Of note, Shimizu et al.
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recently showed that non-professional APCs, such as T and NK
cells, can stimulate iNKT cell activation when they presented
aGC in a cell-associated form.
11,13 They also showed that tumors
lacking costimulatory molecules, such as B16 melanoma and EL4
thymoma, can induce the activation of iNKT cells and NK cells
in vivo when formulated to present aGC. These observations
together raise an interesting question if iNKT ligand-loaded non-
professional APC could act as an efficient APC in generating CD8
T cell response against the peptides loaded on their surface MHC
class I. If this is true, it might be possible to use tumor cell itself or
pathogen-infected cells to generate tumor- or pathogen-specific
cytotoxic T cell immunity, which would be much easier, cost-
effective and practical in clinical settings.
Therefore in the present study, we tested whether conventional
T cells- as a surrogate CD1d-expressing non-professional APC-
can actively interact with iNKT cells and CD8 T cells in the
presence of an iNKT cell ligand and MHC class I-restricted
peptide. Our results showed an efficient activation of iNKT cells
and antigen-specific CD8 T cells in mice vaccinated with T cells
presenting both aGC and peptide on the same cells, which
induced an effective immunity against microbial infection and
tumor. Moreover, vaccination with aGC-pulsed thymoma
generated a tumor-specific cytotoxic T cell response in vivo.
Thus, in the presence of iNKT cell help, non-professional APC,
such as T cells, can stimulate cytotoxic T cell function, providing
an alternative means of cell vaccination method.
Results
Vaccination with aGC-loaded EG-7 generates CD8
+ T cell-
dependent antitumor activity. We first asked whether vaccination
with tumor cells of T cell origin can trigger anti-tumor activity,
when manipulated to present aGC. To track tumor-specific T cell
responses more efficiently in vivo, we employed ovalbumin-
expressing EL4 thymoma (EG-7) as our tumor model. To address
protective antitumor activity by vaccination with aGC-loaded
EG-7, we vaccinated mice with irradiated EG-7 co-cultured
with 1 mg/mL of aGC overnight. EG-7 cells incubated with the
same volume of solvent (5 ml/mL of 0.5% polysorbate) were
used as control (EG-7/veh). After extensive washing, these cells
were i.v. injected into syngenic naïve mice. These mice were
subcutaneously implanted with live EG-7 and the tumor volume
and survival were monitored daily. Mice were sacrificed when
tumor diameters reached 20 mm. As depicted in Figure1A
and B, the vaccination with EG-7/aGC significantly reduced
the growth of solid tumors and induced prolonged survival in
comparison to those of EG-7/veh group. Tumors affect
myelopoiesis and induce the expansion of CD11b
+Gr-1
+
Figure1. Vaccination with aGC-loaded EG-7 generated preventive
antitumor activity. (A–D) EG-7 cells were co-cultured overnight with
1 mg/ml of aGC (EG-7/aGC) or vehicle followed by irradiation (50 Gy).
C57BL/6 mice (n = 7 per group) were vaccinated with EG-7/veh,
EG-7/aGC or untreated (Nil). One week later, all mice were
subcutaneously injected with 1   10
6 live EG-7 cells and the survival
(A) and tumor size (B) were checked. (C) At the 3 weeks later, splenocytes
were isolated from tumor bearing mice and analyzed by flow cytometer
after staining with anti-CD11b, anti-Gr1, anti-CD19, anti-CD4 and
anti-CD8 antibodies. (D) Splenocytes were restimulated with SIINFEKL in
the presence of Golgi-Plug for 5 h before intracellular staining of IFNc on
OVA specific T cells. *p , 0.05, **p , 0.005, p values were calculated
with 2-way ANOVA (A), Kaplan-Meier method (B) or Student’s t-tests
(C and D) in comparison with the EG-7/veh group.
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myeloid-derived suppressor cell (MDSC) in the bone marrow,
blood, spleen.
14 Of note, we also observed a great decrease of
CD11b
+Gr-1
+ population in the spleen of EG-7/aGC vaccinated
mice (, 4%) compared with that of EG-7/veh group (. 20%)
(Fig.1C), another indicative of antitumor activity induced by
the vaccination. Importantly, mice vaccinated with EG-7/aGC
showed higher numbers of CD8
+ T cells producing IFNc upon
SIINFEKL stimulation (Fig.1D). These results overall indicate
the induction of anti-tumor activity as well as tumor-specific
CD8
+ T cell responses upon the vaccination with EG-7/aGC
in vivo.
Therefore, we next examined if the observed anti-tumor
activity by vaccination with EG-7/aGC depends on CD8
+ T cells.
We injected anti-CD8 depleting antibody into the vaccinated
mice before we transplanted live EG-7 cells into them. Depletion
of CD8
+ cells greatly decreased the protective anti-tumor activity
by vaccination with EG-7/aGC (Fig.2A) and the survival of
vaccinated mice (Fig.2B). Taken together, these results indicate
that antitumor immunity generated by aGC-loaded EG-7 is, at
least in part, mediated by CD8 T cells.
Vaccination with aGC-loaded EG-7 induces ova-specific
cytotoxic responses. Our EG-7 tumor models (Fig.1) and
CD8 depletion experiment (Fig.2) raised a hypothesis that tumor
cells of T cell origin, when they present iNKT ligand, are able to
induce cytotoxic T cell response specific for endogenous tumor
antigens. To test our hypothesis, we co-cultured EG-7 cells with
aGC or vehicle before being irradiated (EG-7/aGC and EG-7/
veh, respectively). To increase the expression of peptide/MHC-I
complex, EG-7 cells were first pre-treated with IFNc. One week
after vaccination, we performed an in vivo CTL assay to deter-
mine the antigen-specific cytotoxicity against SIINFEKL-loaded
syngenic splenocytes
11. When injected into naïve syngenic mice,
EG-7/aGC resulted in an evident peptide-loaded target cell lysis
whereas EG-7/veh did not (Fig.3A; -0.37% and 72.8% lysis,
respectively). To examine if CD8
+ T cells in the vaccinated mice
directly kill target cells in an antigen-specific way, we performed an
in vitro CTL assay with purified CD8
+ T cells from the vaccinated
mice by analyzing caspase-3 activation in the target cells. As
depicted in Figure3B, the CD8
+ T cells from the EG-7/aGC
vaccinated mice induced a significantly higher percentage of
caspase-3 cleavage in the target cells than those from the EG-7/veh
vaccinated mice. In addition, the effective target lysis in EG-7/
aGC-vaccinated mice was associated with increased antigen-
specific IFNc
+ granzyme B
+ CD8 T cells in the spleen (Fig.3C).
To further characterize the antigen-specific CD8 T cells, we
adoptively transferred CFSE-labeled OT-I T cells (CD45.2) into
congenic mice (CD45.1). The recipients were vaccinated with
either EG-7/veh or EG-7/aGC and CD45.2
+ cells were analyzed
five days later. OT-I T cells in mice vaccinated with EG-7/veh
underwent an extensive proliferation, but expressed little IFNc
(, 10%) or granzyme B (, 3%). By contrast, significantly higher
population of OT-I T cells in EG-7/aGC-vaccinated mice
expressed IFNc (. 50%) and granzyme B (. 8%) (Fig.3D).
Taken together, these data demonstrate that aGC-loaded EG-7
thymoma induced tumor-specific CD8
+ T cells to differentiate into
cytotoxic effector T cells expressing high levels of IFNc and
granzyme B in vivo.
aGC induces cytotoxic T cell response to T cell-associated
antigens. Ourstudythusfarshowedthat,withhelpofaGC,tumors
of T cell origin can trigger tumor-specific cytotoxic T cell responses.
Therefore we next asked if conventional T cells can also act as
antigenpresenting cells andtriggercytotoxicT cell responses invivo,
whenformulatedtopresentaGC.A previousstudyby Shimizuetal.
showed that T cells, purified by negative selection using magnetic
beads and when loaded with aGC, stimulate iNKT cells in vivo.
13
To further assess iNKT cell activation by T cells, we first sorted
Figure2. CD8 T cells play a critical role in mediating antitumor activity. (A and B) C57BL/6 mice were vaccinated with EG-7/veh or EG-7/aGC on day -7
(n = 5 per group). EG-7/aGC vaccinated mice were intraperitoneally injected with CD8 depleting Ab (563.8) on day-3 and -1. On day 0, all mice were
subcutaneously injected with 1   10
6 live EG-7 cells and the tumor volume (A) and the survival (B) were checked. *p , 0.01, **p , 0.005, p values
were calculated with 2-way ANOVA (A) or Kaplan-Meier method (B) in comparison with EG-7/veh and EG-7/aGC
+rIgG or EG-7/aGC
+rIgG and
EG-7/aGC
+anti-CD8 group.
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NK1.1
2CD8
2CD19
2CD11b
2CD11c
2Gr-1
2I-Ab
2CD4
+ cells
from the lymphoid cells of C57BL/6 mice. These cells were virtually
all CD3
+CD1d
+, indicating no contamination of professional APC
(Fig.4A). The sorted cells were loaded with aGC (T/aGC) or with
vehicle (T/veh) and were i.v. injected into syngenic naïve mice.
When we analyzed splenocytes six hours after the injection, we
observed that CD1d-tetramer
+ cells in mice receiving T/aGC
produced IFNc
+ whereas the same population in mice receiving
T/veh did not produce IFNc (Fig.4B). Therefore CD4
+ Tc e l l s
efficiently triggered iNKT cell activation in vivo when they were
manipulated to present aGC.
We next asked whether T/aGC can induce antigen-specific
cytotoxicity when they were additionally pulsed with MHC class
I-restricted peptide. SIINFEKL peptide (1ng/mL) was added to
T cells in the last one hour when they were incubated with aGC
or vehicle (T/aGC/pep and T/veh/pep, respectively). After
extensive washing, C57BL/6 mice were immunized with T/veh/
pep or T/aGC/pep. One week later, we performed an in vivo
CTL assay to determine the antigen-specific cytotoxicity against
SIINFEKL-loaded syngenic splenocytes. Mice vaccinated with
T/aGC/pep showed complete lysis of target cells while mice
vaccinated with T/veh/pep did not (Fig.4C).
Figure3. Vaccination with aGC-loaded EG-7 generates OVA-specific cytotoxic T cell response in vivo. (A and B) EG-7 cells were cocultured overnight with
1 mg/ml of aGC (EG-7/aGC) or vehicle (0.5% polysorbate, EG-7/veh) followed by irradiation (50 Gy). C57BL/6 mice (n = 3 per group) were vaccinated with
EG-7/veh, EG-7/aGC or left untreated (Nil). (A) One week later, an in vivo CTL assay for SIINFEKL was performed. CFSE
high, peptide-pulsed target; CFSE
low,
peptide-unpulsed control. (B) One week after vaccination, CD8
+ T cells were isolated and incubated with 1 mg/mL peptide-pulsed splenocytes that had
been labeled with DDAO-SE for 2 h. The cells were fixed, permeabilized and stained with anti–cleaved caspase-3 mAb. The levels of cleaved caspase-3
in the DDAO-SE-positive cells were analyzed by flow cytometry. Data shown are representative FACS plots (upper panels) and mean ± SE (lower panel).
*p , 0.05, in comparison with EG-7/veh group. (C) One week after the vaccination, splenocytes were isolated and restimulated with SIINFEKL for 5 h in
the precence of Golgi-Plug before intracellular staining of granzyme B and IFNc. (D) Ovalbumin-specific CD8 T cells were isolated, labeled with 10 mmol/L
CFSE and i.v. transferred into their syngenic mice as described in Figure1. On the following day, mice were i.v. injected with irradiated EG-7 cells
manipulated in vitro with indicated conditions. Five days later, lymphoid cells from the spleen of the recipient mice were restimulated with SIINFEKL for
5 h before intracellular staining of granzyme B and IFNc. Data are representative of at least two separate experiments. *p , 0.05, **p , 0.01, in
comparison with non-treated (Nil) group.
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To analyze whether T/veh/pep vaccination results in cytotoxic
function of antigen-specific CD8 T cells, we isolated CD8
+ T cells
from OT-I mice, labeled them with 10 mM CFSE before
transferring into C57BL/6 mice, which were then vaccinated with
T/veh/pep or T/aGC/pep. When OT-I cells in the spleen of
recipients were analyzed 48 hours after vaccination, both types of
T cell vaccination induced the proliferation of OT-I T cells in
vivo, although the proportion of T cells that had undergone over
five times of division was higher in mice receiving T/aGC/pep
vaccination than those with T/veh/pep (Fig.4D, upper panels).
More importantly, OT-I T cells in mice vaccinated with T/aGC/
pep displayed remarkably higher expression of granzyme B and
IFNc compared with those in T/veh/pep-vaccinated mice
(Fig.4D, middle and lower panels). These data demonstrate that
in response to an antigen on CD4 T cells as a non-professional
APC, although antigen-specific CD8 T cells could proliferate,
their functional differentiation into cytotoxic cells could only
occurr in the presence of iNKT cell ‘help’.
T/aGC/Pep vaccination confers protection against Listeria
monocytogenes and melanoma. We next tested whether the
cytotoxic T cell response generated by T/aGC/pep vaccination is
effective enough in suppressing the growth of intracellular bacteria
and tumor in an antigen-specific manner. We first employed
L. monocytogenes infection model since clearance of this bacterium
is largely dependent on CD8 T cell response. Mice were vaccin-
ated with T/aGC, T/aGC/pep or peptide-pulsed dendritic cells
(DC/pep) as a control. Ten days later, the vaccinated mice were
i.v. injected with L. monocytogenes expressing OVA and the bacterial
burden in the spleen and liver was measured. As expected, mice
vaccinatedwith DC/pepshowedsignificantlylowerbacterialburden
in both spleen and liver compared with non-vaccinated mice
(Fig.5A). Compared with non-vaccinated group, mice vaccinated
with T/aGC showed slightly lower bacterial burden, especially in
the liver. In contrast, mice vaccinated with T/aGC/pep also showed
significantly lower bacterial burden in both organs, which is
comparable to those of DC/pep-vaccinated mice (Fig.5A).
Figure4. Injection of conventional CD4 T cells coated with SIINFEKL and aGC induces a functional cytotoxic T cell response. (A) Lymphoid cells from
spleen and lymph nodes of C57BL/6 mice were stained with FITC-conjugated anti-CD19, anti-NK1.1, anti-Gr-1, anti-CD11b, anti-CD11c, anti-CD8a, anti-I-
Ab antibodies together with APC-conjugated CD4 Ab. Lineage negative and CD4
+ cells were sorted by FACSAria. The sorted cells were stained with PE-
conjugated anti-CD3 or anti-CD1d Ab. Filled histogram is isotype control. (B) Sorted CD4
+ T cells were co-cultured with aGC (1 mg/ml). Cells were washed
and intravenously injected into syngenic mice. Six hours later, lymphoid cells from spleen were stained with CD1d-tetramer and CD19 before intracellular
IFNc staining. CD1d-tetramer
+CD19
- cells were gated and analyzed. (C) The sorted CD4
+ T cells were co-cultured with aGC (1 mg/ml) or vehicle (0.5%
polysorbate) for 16 h including 1 h pulse with SIINFEKL. Cells were washed and intravenously injected into syngenic mice. One week later, syngenic
lymphocytes were either loaded with 1 mmol/L peptides or left untouched before being labeled with CFSE at different concentrations (10 and 1 mmol/L,
respectively). Equal numbers of the two populations were mixed and injected i.v. into mice. Eighteen to 24 h later, lymphoid cells from spleen and lymph
nodes were analyzed to assess peptide-specific killing. (D) OT-I T cells were isolated using anti-CD8 microbeads and AutoMacs. These cells were labeled
with 10 mmol/L CFSE and i.v. transferred into their syngenic mice. On the following day, mice were i.v. injected with T cells manipulated in vitro with
indicated conditions. Forty-eight hours later, lymphoid cells from the spleen of the recipient mice were stained with phycoerythrin (PE)-conjugated anti-
Va2 antibody and then analyzed by flow cytometry. For intracellular Granzyme B and IFNc staining, cells were restimulated with SIINFEKL for 5 h before
intracellular staining of these molecules according to manufacturer’s instruction. Data are representative of at least two independent experiments.
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To assess if the vaccinated mice were also resistant to tumor
growth, we i.v. injected OVA-expressing B16 melanoma cells into
the vaccinated mice. Fourteen days later, we counted tumor foci
in the lung of recipients. Compared with non-vaccinated mice,
mice vaccinated with T/aGC had less tumor foci (Fig.5B). On
the other hand, fewer tumor foci were found in mice vaccinated
with T/aGC/pep or DC/pep (Fig.5B). Intracellular staining of
peripheral blood mononuclear cells after peptide restimulation
revealed that both DC/pep and T/aGC/pep vaccinations
efficiently induced peptide-specific IFNc-producing CD8 T cells
(Fig.5C), which correlated well with anti-Listeria and anti-
metastatic activity in the vaccinated mice. Collectively, these data
demonstrate that vaccination with T/aGC/pep established
protective immunity against intracellular bacteria and tumor in
a peptide-specific manner.
T cells simultaneously presenting iNKT and class I-restricted
ligands directly induce antigen-specific cytotoxicity. We next
sought to elucidate the mode of action in the efficient induction
of peptide-specific cytotoxicity during T/aGC/pep vaccination.
When we vaccinated CD1d-deficient mice with T/aGC/pep, we
did not observe peptide-specific cytotoxicity in our in vivo
CTL assay (Fig.6A). Therefore, the antigen-specific cytotoxicity
elicited by T/aGC/pep requires iNKT cells in vivo.
Next we asked if vaccinated T cells directly stimulate CD8
T cells or require host APC. We utilized bm-1 mouse whose cells
are able to load SIINFEKL onto their MHC I, but the resulting
complex cannot be recognized by OT-I TCR due to a mutation
in the H-2K region.
15 In this experiment, vaccination with
T/aGC/pep using T cells from bm-1 mice failed in induction
of antigen-specific target cell lysis (Fig.6B), indicating that
appropriate MHC/peptide complex on the vaccinating T cells is
essential and that they probably directly primed OT-I cells.
Since aGC and class I peptide are both presented by the same
T cells, this suggests that iNKT ligand may provide a “dangerous”
Figure5. Vaccination with T cell-based vaccine generates protective immunity against L. monocytogenes infection and tumor challenge. C57BL/6 mice
(n = 3 mice per group) were vaccinated with the indicated cellular vaccine (day 0) before they were challenged with 5   10
4 live L. monocytogenes
expressing OVA (day 10). Three days after the bacterial challenge, bacterial burden in spleen and liver was measured (A). Data are a representative of
three separate experiments. (B) C57BL/6 mice (n = 3 mice per group) were vaccinated with the indicated cellular vaccine (day 0). Ten days later, recipients
were intravenously challenged with live 2   10
5 B16-OVA. Two weeks after the tumor challenge, tumor foci in the lung were measured. (C) PBMC was
isolated in mice vaccinated with the indicated cellular vaccine and restimulated with SIINFEKL in the presence of Golgi-Plug for 5 h before intracellular
staining of IFNc. Data are mean ± SE *p , 0.05, **p , 0.01, ***p , 0.001 in comparison with non-treated (Nil) group. Data are representative of two
separate experiments.
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signal to the immune system. To test this hypothesis, C57BL/6
mice were vaccinated with T/pep in combination with either
soluble aGC (2mg, i.p.) or T/aGC. In mice vaccinated with the
former combination, little peptide-specific CTL was generated
(Fig.6C, 13.4% vs. 97.2% lysis in T/aGC/pep-vaccinated mice).
Moreover, mice vaccinated with T/aGC plus T/pep only showed
a moderate peptide-specific CTL, significantly less efficient than
that of T/aGC/pep (Fig.6C, 47.2% lysis vs 97.2% in T/aGC/pep-
vaccinated mice). Thus, these data demonstrate that the vaccinating
T cells act as direct stimulators for both iNKT and CD8 T cells in
vivo and that presentation of aGC and peptide by the same T cell is
the most efficient regimen in generating antigen-specific CTL.
Cytokine and costimulation requirements in the CTL
response elicited by T/aGC/Pep. Upon activation, iNKT cells
promptly produce a wide range of cytokines including IL-4 and
IFNc. IL-4 produced by activated iNKT cells was shown to
promote CD8 T cell proliferation.
16 IFNc and IL-12 produced
upon iNKT and DC interaction mediate anti-tumor activity.
17,18
Recent studies showed that IL-21 is produced by iNKT cells upon
TcR stimulation and regulates the activation and expansion of
iNKT cells.
19,20 Therefore, we asked whether these cytokines
producedafteriNKTcellactivationhadanyroleinthegenerationof
CTL in our T cell vaccine model. We vaccinated IL-4
2/2,I F N c
2/2,
IL-12 p35
2/2 or IL-21
2/2 mice with T/aGC/pep and performed in
vivo CTL assay. As depicted in Figure7A, we observed a complete
peptide-specific CTL activity in all of cytokine-deficient mice we
tested. Thus, none of these cytokines is necessary in the generation
of CTL activity by the T cell vaccine.
Costimulatory signals are essential in regulating the activation
and expansion of iNKT cells. Moreover, CD28 and ICOS signals
are required for the anti-tumor activity of activated iNKT
cells such as cytotoxicity and anti-metastatic activity.
2,21-23
Activated T cells express CD80 and CD86 and may regulate
immune response through T:T interaction.
24,25 Therefore we
asked whether these costimulatory factors were necessary for the
induction of CTL in our model. T cells were isolated from
C57BL/6(WT), B7
2/2 (B7.1
2/2B7.2
2/2), B7h
2/2 or B7B7h
2/2
and loaded with aGC and SIINFEKL ex vivo. The T/aGC/pep
were injected into WT mice and in vivo CTL assay was
performed. As depicted in Figure7B, we observed a normal target
cell lysis in mice vaccinated with costimulation-deficient T cells.
Thus, the induction of peptide-specific cytotoxicity by the T cell
vaccine does not require B7 and B7h costimulation.
Discussion
In the present study, we showed that vaccination with con-
ventional CD4 T cells presenting both CD1d-aGC and MHC
Figure6. Peptide and aGC on the same T cells are required for the optimal priming of CTL by iNKT-mediated T cell vaccine. (A) C57BL/6 (WT) or CD1d
2/2
mice were vaccinated with T cells co-pulsed with aGC and SIINFEKL (1   10
6 per mouse). (B) T cells from WT or bm-1 mice were co-pulsed with aGC and
SIINFEKL before being i.v. injected into WT mice. (C) C57BL/6 mice were vaccinated with T cells co-pulsed with aGC and SIINFEKL (1   10
6 per mouse) or
‘a combination of T cells pulsed with SIINFEKL and of T cells pulsed with aGC’ (1   10
6 each) or T cells pulsed with SIINFEKL plus free form of aGC (i.p.).
CFSE
high, peptide-pulsed target; CFSE
low, peptide-unpulsed control. Data are a representative of at least two separate experiments.
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class I-restricted peptide triggered iNKT cell activation and
generated an antigen-specific cytotoxic T lymphocyte response in
vivo. Mice receiving this novel T cell vaccine were resistant to
L. monocytogenes infection as well as to tumor challenge in an
antigen-dependent manner. Moreover, vaccination with aGC-
pulsed T cell lymphoma also induced CTL response specific for
an endogenous tumor antigen. Mechanistic analyses indicate
that the vaccinated T cells directly stimulated peptide-specific
cytotoxic T cells and that the CTL responses induced by these
‘T cell vaccines’ were independent of cytokines such as IFNc,
IL-12 and IL-21. Therefore T cells as well as tumors of T cell
origin can act as antigen-presenting cells that efficiently trigger
cytotoxic T cell responses, when they are formulated to stimulate
iNKT cells in vivo.
Dendritic cells loaded with various iNKT ligands are potent
inducer of T cell immunity. We recently showed that B cells co-
pulsed with aGC and class I peptide also induce antigen-specific
CTL response in vivo as efficiently as well.
11 Moreover, our recent
study showed that B lymphoma cells loaded with aGC elicited a
strong protective immunity that is dependent on CD4 T cells.
12
However, it has been unclear whether non-professional APC in
the presence of iNKT cell help could induce T cell effector
function. In the present study, we found that CD8 T cells were
activated by antigens presented by CD4 T cells and proliferated
extensively. However, they did not produce significant amounts
of IFNc or Granzyme B that are associated with cytotoxic effector
function, indicating that CD4 T cells are not an efficient APC. It
is possible that T cells, like other non-professional APC, do not
express high levels of costimulatory molecules, which is required
for CD8 T cell effector function.
26 We have also previously
observed this type of non-productive activation in CD8 T cells
reactive to a tissue antigen, which is mediated by PD-1-PDL1
interaction.
27 In the presence of aGC and hence iNKT “help,”
antigen-specific CD8 T cells were able to undergo effector
differentiation by the CD4 T cell vaccine that results in protection
against infection and tumor. Since iNKT ligands are either
derived from infectious agents or induced during infection, their
presence on non-professional APC may provide a “dangerous”
signal to the immune system and, through iNKT cells, “license” a
productive T cell activation and their effector differentiation.
How iNKT cell help CD8 cell effector differentiation remains
unclear at this stage. After activation, iNKT cells promptly
produce a wide range of cytokines which can further activate
themselves and other immune cells including NK, DC, T and B
cells. IFNc and IL-12 are critical mediators for T cell immunity.
IFNc produced by iNKT cells and NK cells mediates anti-
angiogenic activity of aGC.
18 IL-12 produced by DC after
interaction with iNKT cells is critical for inducing IFNc in iNKT
cells.
17 However, in our T cell vaccine model, neither IFNc nor
IL-12 was required for CTL generation. Recent studies suggest
that IL-21 is a crucial cytokine for iNKT cell activation and
function.
19,20 However, an efficient induction of CTL response
by our T cell vaccine in IL-21-deficient mice excludes the role of
this cytokine in the generation of CTL response in our model.
Figure7. Molecular requirements for efficient indication of CTL by iNKT-mediated T cell vaccine. (A) C57BL/6 mice (WT) or various cyokine-deficient mice
with C57BL/6 background were vaccinated with T cells copulsed with aGC and SIINFEKL. (B) Pure CD4
+ T cells were isolated from C57BL/6 (WT), B7
2/2,
B7h
2/2 or B7B7h
2/2 as described in Figure1. Isolated T cells were co-pulsed with aGC and SIINFEKL ex vivo before injected into WT recipient. A week
later, an in vivo CTL assay was performed. CFSE
high, peptide-pulsed target; CFSE
low, peptide-unpulsed control. Data are representative of three separate
experiments.
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Moreover, although vaccinated T cells were found to directly
stimulate iNKT and CD8 T cells, this action does not appear to
require costimulation. We recently found that dendritic cells
loaded with aGC induced iNKT cell activation in the absence of
B7 and B7h (data not shown). It is unclear at this stage whether
there is any signal in addition to TcR that is required for iNKT
and CD8 T cell activation by our T cell vaccine.
Nonetheless, T cells loaded with an iNKT ligand serves as
a potent cellular vaccination approach. A mild suppression of
tumor growth and L. monocytogenes growth was observed in mice
vaccinated with T/aGC, indicating that an effective innate
immunity was induced. However, vaccination with T/aGC/pep
was far more effective in eliciting CD8 T cell immunity and
specifically suppressing tumor growth and L. monocytogenes
growth, which was comparable to DC vaccination. Based on
our results, we propose that T cells from individuals infected with
T cell-tropic pathogens—such as HIV—could be used as a source
of cellular vaccine for triggering pathogen-specific cytotoxic
response. Notably, i.v. injection of irradiated EG-7 thymoma
did not induce an OVA-specific CTL response; however, injec-
tion of aGC-loaded, irradiated EG-7 efficiently generated an
OVA-specific CTL response. As a result, vaccination with aGC-
loaded, irradiated EG-7 induced a potent anti-tumor activity
against challenge with live EG-7, which was CD8
+ T cell-
dependent. Therefore we propose that vaccination of aGC-loaded
T lymphoma may result in the generation of tumor-specific CTL
response.
Our finding is novel in that non-professsional APCs are also
able to trigger cytotoxic T cell immunity with the help of iNKT
cell. T cell is a major population in blood and can be easily
expanded and cultured in vitro. Although resting human T cells
express little CD1d, activated T cells as well as thymocytes in
humans express CD1d on their surface.
28 Moreover, cutaneous
T cell lymphomas in humans have been reported to express high
levels of CD1D.
29 These observations suggest that our findings
can be directly applicable in clinical settings. Therefore, tumors
that are not professional APC in origin, especially thymoma and
T lymphoma, could be used as efficient APC for cytotoxic T cell
anti-tumor immunity when they are formulated to stimulate
iNKT cells. Our T cell vaccine strategy will provide an alternative
cellular vaccine regimen that can induce the efficient activation of
both innate and adaptive immunity in vivo.
Materials and Methods
Mice. C57BL/6, OT-I, C57BL/6
bm1 (bm-1), IL-4
2/2, IFNc
2/2,
IL-12p35
2/2, CD80
2/2CD86
2/2 (B7
2/2) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). B6.SJL
mice (Ly5.1) were purchased from Taconic Farm. B7h
2/2 and
B7B7h
2/2 mice were generated and backcrossed in our labora-
tory.
26,30 CD1d
2/2 mice were bred in our animal facility. IL-21
2/2
mice were previously described
31 and bred in our animal facility.
All mice were kept under specific pathogen-free conditions in
our animal facility (MD Anderson Cancer Center). All animal
studies were approved by the Institutional Animal Care and Use
Committee of MD Anderson Cancer Center.
Preparation of T and dendritic cells. Conventional CD4
T cells were purified from lymphoid cells of C57BL/6 mice by
sorting CD8
2 NK1.1
2 CD19
2 CD11b
2 CD11c
2 Gr-1
2 I-Ab
2
but CD4
+ cells with a FACS Aria
1. These cells were . 99.5%
CD3
+CD4
+ and CD1d
+. In some experiments, CD4 T cells were
isolated from CD1d
2/2 or bm-1 mice. Bone marrow-derived DCs
were generated by culturing bone-marrow cells in the presence of
GM-CSF and IL-4 for 6 d. Sorted T cells were co-cultured with
aGC (1 mg/mL) or the same volume of solvent vehicle (5 ml/mL
of 0.5% polysorbate) overnight. In some experiments, these cells
were further incubated with SIINFEKL peptide for 1 h.
EG-7 cells were cultured in the presence of IFNc (100 ng/mL)
for 48 h including overnight culture with aGC or vehicle as
described above. These EG-7 cells were washed and irradiated
with Cs source (50 Gy) before i.v. injected into syngenic mice.
CFSE-labeled OT-I adoptive transfer. Ovalbumin-specific
CD8 T cells were isolated from the lymphoid cells of OT-I mice
using anti-CD8 magnetic beads and AutoMacs (. 92% are
Va2
+). These cells were labeled with 10 mM of CFSE and i.v.
transferred into C57BL/6 mice. In some experiment, Ly5.1
congenic mice were used as recipients. Recipient mice were i.v.
injected with CD4 T cells or irradiated EG-7 cells formulated ex
vivo with indicated conditions. Two to five days later, lymphoid
cells from the spleen of recipient mice were isolated and cultured
with 0.1 mg/mL SIINFEKL in the presence of GolgiPlug
(1 mL/mL) for 5 h. These cells were stained with phycoerythrin
(PE)-conjugated anti-Va2 Ab or PE-conjugated anti-Ly5.2 Ab
before permeabilized and further stained with APC-conjugated
anti-IFNc Ab or Alexa 647-conjugated anti-granzyme B Ab.
Total 1   10
6 events were collected and CFSE
+ PE
+ cells were
gated and analyzed by FACS Calibur.
iNKT cell staining. For intracellular staining of IFNc in iNKT
cells, splenocytes and liver mononuclear cells from mice injected
with vehicle-pulsed T cells, aGC-loaded T cells were stained with
PE-conjugated aGC-loaded/CD1d-tetramer together with FITC-
conjugated anti-CD19 Ab (for splenocytes) or FITC-conjugated
anti-TCR  Ab. These cells were permeabilized and stained
with APC-conjugated anti-IFNc Ab. CD19
2CD1d-tetramer
+ or
TCR 
+CD1d-tetramer
+ cells were defined as iNKT cells and
analyzed.
In vitro and vivo cytotoxic T lymphocytes response assay. The
in vitro SIINFEKL- specific cytotoxic T lymphocytes response
was measured using a caspase-3 cleavage assay.
32 In brief, CD8 T
cells were isolated from the vaccinated mice by using anti-CD8
microbeads and magnetic activated cell sorting. Splenocytes from
syngenic mice were used as target cells after labeled with DDAO-
SE and 1 mg/mL peptide. The sorted CD8 T cells were co-
cultured with the target splenocytes at a 1:1 ratio for 2 h at 37°C.
The cells were permeabilized and stained with PE-conjugated
anti-cleaved caspase-3 antibody. The percentage of cleaved
caspase-3-positive cells among DDAO-SE-labeled target cells
were analyzed by flow cytometry. The in vivo SIINFEKL-specific
cytolytic activity of CD8 T-cell responses was measured as
described previously.
33 Briefly, splenocytes were either loaded
with 1 mg/mL peptide or left untouched before being labeled with
CFSE at different concentrations (10 and 1 mmol/L, respectively).
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Equal numbers of the two populations were mixed and injected
i.v. into mice. 18–48 h later, splenocytes from the recipients were
analyzed by flow cytometer to assess the peptide-specific killing.
The ovalbumin-specific lysis was calculated as follows: r =%
CFSE
low / % CFSE
high and % lysis = [1 – (runprimed / rprimed)]  
100, where r is the ratio.
L. monocytegenes infection and tumor challenge. C57BL/6
mice were vaccinated with the indicated cellular vaccine (day 0)
before they were i.v. challenged with 5   10
4 live L. monocytogenes
expressing OVA (day 10). Three days after the bacterial challenge,
bacterial burden in spleen and liver was measured by culturing
serially diluted homogenized spleen and liver on brain-heart
infusion agar plate. Peptide-specific IFNc-secreting cells in
PBMC were measured after restimulation with SIINFEKL in
the presence of Golgi-Plug for 5 h followed by intracellular
staining of IFNc. In a tumor challenge model, mice vaccinated
with indicated cellular vaccines were i.v. challenged with live 2  
10
5 B16-OVA 10 d after vaccination. Two weeks after the tumor
challenge, tumor foci in the lung were counted and OVA-specific
CD8 T cells were measured after staining with PE-conjugated
OT-I tetramer in combination with FITC-conjugated anti-CD8
Ab. To test protective antitumor effect by autologous vaccine,
aGC loaded EG-7 cells were irradiated before i.v. vaccination
(1x10
6 cells). At 7 d later, mice were s.c. challenged 1   10
6 live
EG-7 cells and then the survival and tumor size of mice were
monitored. To deplete CD8 T cells, 100 mg of anti-CD8 mAb
(563.8) was i.p. injected twice (on day-3 and -1) into the mice
vaccinated with EG-7/aGC on day-7. On day 0, mice were i.v.
challenged with 1   10
6 live EG-7 cells and the survival and
tumor volume were monitored. Tumor volume based on caliper
measurements were calculated by the modified ellipsoidal
formula, 1/2(Length   Width
2).
Statistics. Statistical values were assessed by the Student’s t-test.
P values were expressed and error bars are SE. The correlation of
tumor volume was analyzed for significance using 2-way analysis
of variance (ANOVA).The Kaplan-Meier method was used to
estimate the survival outcomes and groups were compared with
log-rank statistic.
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